Fairchem Organics Ltd
FAIRCHEMORFairchem Organics Ltd's price has outrun its earnings. −26.2% in a year against EPS −73.9% — the market is paying now for delivery later.
The sharpest disagreement: the price moved −26.2% in a year while annual EPS moved −73.9% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a downtrend (93 weeks in) while the P/E sits at the 96th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +525.4% year on year, and 146% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Fairchem Organics Ltd trades at ₹704, in a downtrend and 93 weeks into that stage. That is +5.1% against its own 200-day average. It sits at 70% of a 52-week range of ₹457 to ₹811. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 17 straight weeks.
Today the stock is in a downtrend — week 93 of stage 4, confirmed. At ₹704 it trades +5.1% versus its 200-day average and sits at 70% of its 52-week range (₹457–₹811).
Against the market, two honest reads. Cumulative: over the last 5.6 years the stock moved +8% while the NIFTY 500 moved +103% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 17 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 96th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Fairchem Organics Ltd trades at 157.0× P/E, at the pricey end of its own range (96th percentile). Its long-run median P/E is 38.2×, measured across 5.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 157.0× is at the pricey end of its own range (96th percentile), against a long-run median of 38.2× measured over 5.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −73.9% against a −26.2% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the −14.4%/yr price move, ~−36.8%/yr came from earnings growth and ~+22.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Fairchem Organics Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −91.6% at the trough to +525.4%, a 2-quarter improving streak (single-quarter readings), ROCE slipping at 3.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −14.5% | −10.8% | +3.0% | — |
| Profit | −72.7% | −48.5% | −32.2% | — |
| EPS | −73.9% | −49.1% | −33.0% | — |
| Share price | −26.2% | −17.1% | −14.4% | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
34.1/100 — rank 16 of 20 in Chemicals - Organic · 87% evidence confidence
Fairchem Organics Ltd scores 34.1 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 16. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 11.4 + 6.3 + 6 + 10.4 = 34.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Fairchem Organics Ltd reported ₹117 Cr of revenue in the Mar 26 quarter, −3.2% year on year. Over 6 years it has compounded at 7.0% a year. The last full year, FY26, came in at ₹460 Cr. The last four reported quarters add to ₹460 Cr.
Fairchem Organics Ltd reported ₹117 Cr of revenue in the Mar 26 quarter, −3.2% year on year. Over 6 years it has compounded at 7.0% a year. The last full year, FY26, came in at ₹460 Cr. The last four reported quarters add to ₹460 Cr.
FY26 revenue came in at ₹460 Cr (−14.5% on the year), capping 6 years at 7.0% compound. The latest quarter (Mar 26) printed ₹117 Cr, −3.2% year on year.
Pace check: the last four quarters averaged −13.8% growth against the decade's 7.0% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −14.5% over the last 4 quarters against −14.0%/yr over the last 8 — stabilising; TTM profit −74.8% vs −63.0%/yr — rolling over.
→ Revenue slipped — did margins hold as it scaled? Next: 6.9% this quarter (+3.2 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Fairchem Organics Ltd's operating margin is 6.9% in the Mar 26 quarter, +3.2 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 5.0% to 17.0%. The current quarter sits inside that band.
Fairchem Organics Ltd's operating margin is 6.9% in the Mar 26 quarter, +3.2 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 5.0% to 17.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 6.9%, +3.2 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 5.0%–17.0%.
Why the margin moved: operating margin went +3.2 pp year on year while gross margin went +2.0 pp — the gain came mostly from the gross line: input costs and pricing.
→ Margins held — did that reach the bottom line? Next: profit +525.4% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Fairchem Organics Ltd earned ₹3.7 Cr of net profit in the Mar 26 quarter, +525.4% year on year. Full-year FY26 profit was ₹6.0 Cr. The 6-year compound rate is −25.5%. That is 3.2% of the quarter's revenue. The same quarter a year earlier earned ₹0.6 Cr. 1 of the last 12 reported quarters were loss-making.
Fairchem Organics Ltd earned ₹3.7 Cr of net profit in the Mar 26 quarter, +525.4% year on year. Full-year FY26 profit was ₹6.0 Cr. The 6-year compound rate is −25.5%. That is 3.2% of the quarter's revenue. The same quarter a year earlier earned ₹0.6 Cr. 1 of the last 12 reported quarters were loss-making.
Mar 26 profit was ₹3.7 Cr, +525.4% year on year. On the full year, FY26 printed ₹6.0 Cr (−72.7%), and the 6-year compound rate is −25.5%.
Why profit moved: revenue contributed −3.2% and the margin +3.2 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +62.5% vs revenue −13.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 146% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 146% of Fairchem Organics Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹42.0 Cr of operating cash against ₹6.0 Cr of profit. After ₹12.0 Cr of capital spending, ₹30.0 Cr was left as free cash.
FY26: operating cash of ₹42.0 Cr against reported profit of ₹6.0 Cr, leaving free cash of ₹30.0 Cr after ₹12.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 146% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 146%: the cash cycle stretched 48 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 1.7× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹54.0 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Fairchem Organics Ltd's cash conversion cycle runs 139 days in FY26, up from 91 days in FY21. Capital spending ran ₹54.0 Cr over the last 3 years. At FY26 sales of ₹460 Cr each day of that cycle holds about ₹1.3 Cr, so roughly ₹175 Cr sits inside the business at any moment.
FY26: debtors at 54 days, inventory at 96 days — roughly 3.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 139 days, looser than FY21's 91.
The full loop: cash goes out to suppliers and production on day 0; stock waits 96 days to sell; customers pay about 54 days after that; and suppliers themselves are paid at 12 days — netting out to the 139-day cycle.
In money terms: at FY26 sales of ₹460 Cr, each day of the cycle holds about ₹1.3 Cr — so the 139-day loop keeps roughly ₹175 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹54.0 Cr over the last 3 fiscal years against ₹31.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹18.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 3% and the ROIC − WACC spread is −9.4 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Fairchem Organics Ltd earns a ROCE of 3% in FY26. Return on invested capital clears the cost of that capital by −9.4 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 1.3% net margin on 1.18× asset turns.
FY26 ROCE is 3%.
🚨 Why the return is what it is — the wiring (FY26): 1.3% net margin × 1.18× asset turns × 1.49× balance-sheet leverage ≈ 2.3% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 2.6% − 12.0% = a −9.4 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.32.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Fairchem Organics Ltd carries total debt of ₹84.0 Cr against shareholder equity of ₹263 Cr as of Mar 26, a debt-to-equity of 0.32. On the annual view that ratio went from 0.27 in FY22 to 0.32 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹84.0 Cr against shareholder equity of ₹263 Cr — a debt-to-equity of 0.32. On the annual view, debt-to-equity went from 0.27 (FY22) to 0.32 (FY26). Read the returns on this page with that leverage in mind.
→ Who owns this, and are they adding or leaving? Next: Promoters added 4.5 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters added 4.5 points of Fairchem Organics Ltd over 8 quarters, the biggest move on the register. That takes promoters to 63.3% of the company. Domestic institutions moved −2.4 points over the same window, to 2.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +4.5 points over 8 quarters to 63.3%; Domestic institutions: −2.4 points over 8 quarters to 2.8%; Foreign institutions: +0.0 points over 8 quarters to 6.3%.
Why the register moved: promoters drove it (+4.5 points), absorbed on the other side by domestic institutions (−2.4 points) — steady accumulation by institutions reading the same numbers this page reads.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Fairchem Organics Ltd: the Z-score reads 6.73. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 6.73 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 6.73.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Fairchem Organics Ltd this page | 157.0× | ₹967 Cr | Turning around | |||
| BASF India Ltd | 38.4× | ₹15,887 Cr | No read | |||
| Fine Organic Industries Ltd | 35.9× | ₹14,804 Cr | Improving | |||
| Elantas Beck India Ltd | 50.3× | ₹7,346 Cr | Mixed | |||
| Balaji Amines Ltd | 42.2× | ₹7,046 Cr | Improving | |||
| Laxmi Organic Industries Ltd | 63.2× | ₹5,053 Cr | Mixed | |||
| Foseco India Ltd | 39.0× | ₹3,805 Cr | — | — | — | — |
| Citurgia Biochemicals Ltd | — | ₹1,884 Cr | No read | |||
| Nitta Gelatin India Ltd | 13.5× | ₹1,489 Cr | Mixed | |||
| Oriental Aromatics Ltd | 379.0× | ₹1,255 Cr | Mixed | |||
| Jyoti Resins and Adhesives Ltd | 14.3× | ₹997 Cr | Topping out | |||
| Sigachi Industries Ltd | 29.9× | ₹974 Cr | Turning around | |||
| Sacheerome Ltd | 33.3× | ₹946 Cr | — | — | — | — |
| Indo Amines Ltd | 11.8× | ₹940 Cr | Consistent | |||
| Gem Aromatics Ltd | 651.0× | ₹930 Cr | No read | |||
| Shri Ahimsa Naturals Ltd | 31.1× | ₹904 Cr | — | — | — | — |
| Valiant Organics Ltd | 25.4× | ₹737 Cr | No read | |||
| OCCL Ltd | 14.6× | ₹724 Cr | No read | |||
| Shree Ganesh Remedies Ltd | 35.1× | ₹636 Cr | Deteriorating | |||
| Valiant Organics Ltd | 33.0× | ₹600 Cr | No read | |||
| GFL Ltd | 11.0× | ₹494 Cr | No read |
Frequently asked questions
What is Fairchem Organics Ltd's share price today?
Fairchem Organics Ltd trades at ₹704, −26.2% over the past year. The company is valued at ₹967 Cr. The stock sits at 70% of its 52-week range of ₹457–₹811, +5.1% versus its 200-day average. On the tape, the price is in a downtrend, 93 weeks in. — as of 24 July 2026.
What were Fairchem Organics Ltd's latest quarterly results?
Fairchem Organics Ltd reported revenue of ₹117 Cr and net profit of ₹3.7 Cr for the Mar 26 quarter. Revenue fell 3.2% and profit rose 525.4% year on year. Earnings per share were ₹2.93. The operating margin was 6.9%, 3.2 pp higher than a year earlier. — as of 24 July 2026.
What is Fairchem Organics Ltd's revenue?
Fairchem Organics Ltd reported revenue of ₹117 Cr in the Mar 26 quarter, −3.2% year on year. For the full FY26 fiscal year, revenue was ₹460 Cr (−14.5%). Over the last 6 years revenue compounded at 7.0% a year. — as of 24 July 2026.
What is Fairchem Organics Ltd's profit?
Fairchem Organics Ltd earned ₹3.7 Cr of net profit in the Mar 26 quarter, +525.4% year on year. Full-year FY26 profit was ₹6.0 Cr. The operating margin ran 6.9% in the latest quarter. — as of 24 July 2026.
What is Fairchem Organics Ltd's market cap?
Fairchem Organics Ltd's market capitalisation is ₹967 Cr at a share price of ₹704. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Fairchem Organics Ltd's P/E ratio?
Fairchem Organics Ltd trades at a P/E of 157.0×, at the 96th percentile of its own 5-year range, against a long-run median of 38.2×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Fairchem Organics Ltd pay a dividend?
Not in its latest year — Fairchem Organics Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 5 of its last 7 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Fairchem Organics Ltd overvalued?
On its own history, Fairchem Organics Ltd looks expensive against its own history: its P/E of 157.0× sits at the 96th percentile of its 5-year range (long-run median 38.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Fairchem Organics Ltd growing?
Yes — Fairchem Organics Ltd is growing: latest-quarter revenue −3.2% year on year, profit +525.4%, and the margin +3.2 pp at 6.9%. The 6-year compound rates are 7.0% (revenue) and −25.5% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Fairchem Organics Ltd performing?
Fairchem Organics Ltd is in a downtrend, 93 weeks in. Its latest quarter's revenue fell 3.2% and profit rose 525.4% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 17 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Fairchem Organics Ltd in?
Turning around — profit growth swung from −91.6% at the trough to +525.4%, a 2-quarter improving streak (single-quarter readings), ROCE slipping at 3.0%. The read comes from the last 12 quarters of growth (revenue growth −3.2% latest, profit growth +525.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Fairchem Organics Ltd in an uptrend?
No — the price is in a downtrend (week 93 of stage 4), trading +5.1% versus its 200-day average and at 70% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Fairchem Organics Ltd beating the market?
On recent form, yes — Fairchem Organics Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 17 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.6 years the stock moved +8% against the NIFTY 500's +103% — behind the index over the full window. — as of 24 July 2026.
Will Fairchem Organics Ltd's share price go up?
This page publishes no price forecast for Fairchem Organics Ltd. What it measures instead: the share price is ₹704, the price is in a downtrend 93 weeks in. Its P/E of 157.0× sits at the 96th percentile of its own 5-year range. — as of 24 July 2026.
Who owns Fairchem Organics Ltd?
Promoters hold 63.3% of Fairchem Organics Ltd, foreign institutions 6.3%, domestic institutions 2.8% and the public 27.6% (latest quarter). The biggest move on the register over the last two years: Promoters added 4.5 points over 8 quarters. — as of 24 July 2026.
Does Fairchem Organics Ltd have too much debt?
It is moderate — Fairchem Organics Ltd's debt-to-equity is 0.32, and operating profit covers the interest bill 6×. FY26 borrowings were ₹84.0 Cr against equity of ₹263 Cr. Read the returns on this page with that leverage in mind — as of 24 July 2026.
What is Fairchem Organics Ltd's capex?
Fairchem Organics Ltd spent ₹54.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹12.0 Cr, with ₹18.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Fairchem Organics Ltd's cash flow?
Fairchem Organics Ltd generated ₹42.0 Cr of operating cash flow in FY26 and ₹30.0 Cr of free cash flow after ₹12.0 Cr of capital spending. Reported profit that year was ₹6.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Fairchem Organics Ltd's profit real cash?
Yes — over the last 3 fiscal years, 146% of Fairchem Organics Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹42.0 Cr against reported profit of ₹6.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
How financially safe is Fairchem Organics Ltd?
On the balance sheet, the Z-score reads 6.73 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 24 July 2026.
Where is Fairchem Organics Ltd in its business cycle?
Fairchem Organics Ltd's FY26 operating margin was 5.0%, against a 7-year band of 5.0%–17.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 6.9%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Fairchem Organics Ltd story?
The sharpest disagreement: the price moved −26.2% in a year while annual EPS moved −73.9% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Fairchem Organics Ltd a stock worth studying right now?
This is not investment advice. The machine read: Fairchem Organics Ltd's price has outrun its earnings. −26.2% in a year against EPS −73.9% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.